Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171015
Status:
COMPLETED
Last Update Posted:
2023-10-18
First Post:
2005-09-10
Brief Title:
VALORY Study of ValsartanHydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
An OpenMulticenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With ValsartanHydrochlorothiazide 16025 Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg in Patients Not Adequately Responding to a 4 Week Monotherapy With Olmesartan Medoxomil 40 mg or Combination Therapy With Olmesartan Medoxomil 20 mg Plus HCTZ 125 mg
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of valsartan 160 mgHCTZ 25 mg in patients not adequately responding to monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan medoxomil 20 mg plus HCTZ 125 mg by testing the hypothesis that valsartan 160 mgHCTZ 25 mg significantly reduces the trough mean sitting diastolic blood pressure MSDBP after a 4-week treatment in the nonresponder population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None